The LUX‐Lung 6 trial further consolidated afatinib in first‐line treatment of NSCLC harboring EGFR mutations, which showed first‐line afatinib significantly improved PFS compared with gemcitabine plus cisplatin (median PFS: 11.0 vs. 5.6 months; HR, 0.28; 95%CI: 0.2, 0.39; p < 0.0001).139. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.